Drugs targeting the central nervous system take significantly longer to develop and get approved than other meds, according to a new analysis. In fact, the report cites that CNS drugs took 20% longer to develop and about 19 months (36%) longer on average than other meds to win FDA approval after clinical trials.
Other content in this Stream
The goal of this study was to identify a CDR quality metric, based upon internal patterns of domain scores that could be used to identify atypical patterns that might be indicative of scoring errors.
The aim of this study was to evaluate the reliability and validity of three computerized neurocognitive assessment tools (CNTs; i.e., ANAM, DANA, and ImPACT) for assessing mild traumatic brain injury.
The purpose of this study was to investigate the predictors of symptom recovery in a prospective sample of emergency department trauma patients with either mTBI or non-mTBI injuries.
As Alzheimer’s disease (AD) drug development moves to earlier, preclinical stages of disease, clinicians, trialists, and regulators have wrestled with the question of how to detect cognitive change...
Objective: Systematic review of possible long-term effects of sports-related concussion in retired athletes.
The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer’s disease.
This review will cover the neuropathologic basis of dementia, provide clinical perspectives on multiple pathologies, and discuss therapeutics and biomarkers targeting overlapping pathologies...